Brett Dovman represents both public and privately held companies in a wide range of corporate and securities matters, including private financings, M&A, public offerings and corporate governance matters.

Download full bio 


  • Ambrx Biopharma – $126 Million IPO 

  • MannKind – $200 Million Convertible Notes Offering 

  • Silverback Therapeutics– $278 Million IPO 

  • Kronos Bio – $288 million IPO 

  • Cooley advises Ascus Biosciences on $46M Series B Round 


  • Benjamin N. Cardozo School of Law Yeshiva University
    JD, magna cum laude, Law Review, 2016

  • Pace University
    MBA, 2009

  • Syracuse University
    BS, Aerospace Engineering

Admissions & Credentials

New York